Minnesota is currently home to 2098 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Minneapolis, Rochester, Saint Paul and Duluth. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
AI in Outpatient Practice for Diagnosing Aortic Stenosis and Diastolic Dysfunction
NCT06580158
Recruiting
Two recently developed artificial intelligence-enabled electrocardiogram (AI-ECG) models have been developed to detect aortic stenosis (AS) and diastolic dysfunction (DD). AI-ECG for AS has a sensitivity of 78% and specificity of 74%, and AI-ECG for DD has a sensitivity of 83% and specificity of 80%. However, these models have never been prospectively applied to diagnose AS or DD, which may be useful for patients and providers from a diagnostic and prognostic perspective and especially in settin... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
12/30/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Aortic Stenosis, Diastolic Dysfunction
Register for Updates
Full-mouth Electronic Toothbrush Vs. Conventional Electronic Toothbrush
NCT06561204
Recruiting
The goal of this randomized, masked-examiner clinical trial is to investigate a full-mouth electronic toothbrush (FMET). The three arms are: 1) FMET + American Dental Association (ADA) approved dentifrice, 2) conventional electronic toothbrush (ETB) + ADA dentifrice and 3) FMET + foam system.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/30/2024
Locations: University of Minnesota School of Dentistry, Minneapolis, Minnesota
Conditions: Toothbrush, Gingivitis, Plaque
Register for Updates
A Study of Sex Differences in Neurocirculatory Control
NCT06261034
Recruiting
The purpose of this study is to investigate potential sex differences in neurocirculatory control of blood pressure in patients with untreated obstructive sleep apnea (OSA).
Gender:
ALL
Ages:
Between 20 years and 70 years
Trial Updated:
12/30/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Obstructive Sleep Apnea
Register for Updates
Thoracic Specimen Registry
NCT04118660
Recruiting
The purpose of the registry will be to support ongoing research in the etiology, early diagnosis, clinical management, and prognosis of lung cancer and other cancers and diseases of the thorax by developing a complete repository of specimens from patients with thoracic disease including but not limited to suspected lung cancer, mediastinal and pleural tumors, lung transplants and from patients at a very high risk of developing other thoracic cancers or other thoracic diseases.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/30/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Thoracic Diseases, Lung Cancer, Lung Transplant
Register for Updates
Adenovirus (RGDCRAdCOX2F)
NCT06693986
Recruiting
This is a single center, Phase I dose finding study of a single direct tumor injection of an RGD modified conditionally replicative adenovirus (RGDCRAdcox2F) in persons with adenocarcinoma of the pancreas. The study is designed to determine the MTD of RGDCRAdCOX2F that corresponds to the maximum desired toxicity of ≤ 20%.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/27/2024
Locations: Masonic Cancer Center, Minneapolis, Minnesota
Conditions: Adenocarcinoma of Pancreas
Register for Updates
A Collaborative Intervention for Improving Cancer Pain Management in Rural and Hispanic Cancer Survivors (ASCENT)
NCT06198010
Recruiting
This clinical trial tests a collaborative pain management intervention (ASCENT) for improving cancer pain in rural and Hispanic cancer survivors. Cancer pain is prevalent, under-treated, and remains a major cause of suffering, impairment, and disability for millions of Americans. Individual pain interventions and care models show promise for cancer pain in controlled settings. Hispanic and rural-dwelling cancer survivors stand to benefit the most from electronic health record innovations, as eac... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/27/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm
Register for Updates
Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes
NCT02915198
Recruiting
This research will help us to learn if the medicine called metformin reduces the risk of death, heart attacks, and/or strokes in Veterans who have pre-diabetes and heart or blood vessel problems.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/27/2024
Locations: Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis, Minnesota
Conditions: Prediabetic State, Atherosclerosis, Metformin
Register for Updates
Understanding of Genetics by Men At Risk for Prostate Cancer
NCT04550845
Recruiting
With this greater certainty regarding prognosis, men with localized prostate cancer are now equipped with make better treatment planning decisions. This study is designed to investigate the understanding of prognostic genetic technology in African American and rural White men at risk for localized prostate cancer.
Gender:
MALE
Ages:
Between 40 years and 95 years
Trial Updated:
12/24/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Prostate Cancer
Register for Updates
CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations
NCT05689021
Recruiting
This phase II trial tests how well abiraterone acetate/niraparib (CJNJ-67652000 \[niraparib/abiraterone acetate fixed-dose combination\]) and prednisone works in treating patients with castration-resistant prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and who have a mutation in the SPOP gene. CJNJ-67652000 (niraparib/abiraterone acetate fixed-dose combination) is a drug which stops certain cancer cells from being able to repai... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
12/23/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Register for Updates
A Prospective Observational Study of Foam Sclerotherapy .
NCT04111692
Recruiting
An observational prospective study to determine the impact of foam sclerotherapy of large, dominant kidney/liver cysts on quality of life outcomes and kidney/liver cyst volumes at up to 12 months of follow-up in patients with autosomal dominant polycystic kidney disease (ADPKD) and autosomal dominant polycystic liver disease (ADPLD).
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
12/23/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Autosomal Dominant Polycystic Kidney, Renal Cyst, Autosomal Dominant Polycystic Liver Disease, Hepatic Cyst
Register for Updates
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
NCT06470243
Recruiting
This phase III trial compares the effect of adding carboplatin to the standard of care chemotherapy drug cabazitaxel versus cabazitaxel alone in treating prostate cancer that keeps growing even when the amount of testosterone in the body is reduced to very low levels (castrate-resistant) and that has spread from where it first started (primary site) to other places in the body (metastatic). Carboplatin is in a class of medications known as platinum-containing compounds. Carboplatin works by kill... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
12/20/2024
Locations: Minnesota Oncology - Burnsville, Burnsville, Minnesota
Conditions: Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Register for Updates
VIDAS® TBI Real Life Performance in Subjects with Mild Traumatic Brain Injury (mTBI)
NCT06449183
Recruiting
Decision Rules for an initial CT-scan in patients arriving to Emergency Department (ED) and presenting a mild traumatic brain injury could be optimized by the use of an objective parameter easily and rapidly measured. This may be the place for serum biomarkers providing a quick and accurate assessment. BioMérieux has now developed an automated assay for the measurement of serum Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin C-terminal Hydrolase (UCH-L1), the VIDAS® TBI assay to fill out th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/20/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Mild Traumatic Brain Injury
Register for Updates